Nivolumab: observed
229 studies: patients on it are followed, or it is given outside a trial. Page 3 of 3. Open to participants first (50), then studies with results posted, then the rest; newest registration first within each.
- Post-ATU Study of NivolumabCompletedNCT03325257Report a problem
- Study of Adverse Renal Effects of Immune Checkpoints InhibitorsCompletedNCT03316417Report a problem
- A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in JapanCompletedNCT03273790Report a problem
- Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic MelanomaCompletedNCT03225365Not applicableReport a problem
- The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in GermanyWithdrawnNCT03205722Report a problem
- Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With NivolumabCompletedNCT03200977Report a problem
- A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanCompletedNCT03165422Report a problem
- Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has SpreadCompletedNCT03165409Report a problem
- Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in MexicoWithdrawnNCT03161613Report a problem
- Immune Checkpoint Inhibitors and Pre-existing Autoimmune DiseasesCompletedNCT03140137Report a problem
- Nivolumab in the Real World: Analysis of the Expanded Use in Spanish PatientCompletedNCT03132493Report a problem
- Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedNCT03129061Phase 1Report a problem
- Expanded Access to Nivolumab (Opdivo)Approved for marketingNCT03126643Report a problem
- Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based TherapyCompletedNCT03114163Report a problem
- Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)CompletedNCT03061955Report a problem
- Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyCompletedNCT02990611Report a problem
- Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyCompletedNCT02940639Report a problem
- Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU ProgramCompletedNCT02933346Report a problem
- IL2 Imaging in Metastatic MelanomaTerminatedNCT02922283Not applicableReport a problem
- Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior ChemotherapyCompletedNCT02910999Report a problem
- Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to NivolumabCompletedNCT02856451Report a problem
- Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeCompletedNCT02847728Report a problem
- RATIO: Rational Approach To Immuno-OncologyCompletedNCT02700971Not applicableReport a problem
- Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.CompletedNCT02600143Report a problem
- Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of ImmunotherapyStatus unknownNCT02581228Report a problem
- Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenNo longer availableNCT02475382Report a problem
- Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation TherapyCompletedNCT02449837Report a problem
- Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaNo longer availableNCT02186249Report a problem
- Expanded Access Program With Nivolumab to Treat MelanomaNo longer availableNCT02142218Report a problem